Page last updated: 2024-10-31

mexiletine and Disease Exacerbation

mexiletine has been researched along with Disease Exacerbation in 1 studies

Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.

Research Excerpts

ExcerptRelevanceReference
"To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)."9.22A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016)
"To determine the safety and tolerability of mexiletine in a phase II double-blind randomized controlled trial of sporadic amyotrophic lateral sclerosis (SALS)."5.22A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. ( Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Weiss, MD1
Macklin, EA1
Simmons, Z1
Knox, AS1
Greenblatt, DJ1
Atassi, N1
Graves, M1
Parziale, N1
Salameh, JS1
Quinn, C1
Brown, RH1
Distad, JB1
Trivedi, J1
Shefner, JM1
Barohn, RJ1
Pestronk, A1
Swenson, A1
Cudkowicz, ME1

Trials

1 trial available for mexiletine and Disease Exacerbation

ArticleYear
A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
    Neurology, 2016, Apr-19, Volume: 86, Issue:16

    Topics: Amyotrophic Lateral Sclerosis; Disease Progression; Dose-Response Relationship, Drug; Female; Follow

2016